Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06334133 · ClinicalTrials.gov registry record · Phase 3
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 1, sponsored by vTv Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06334133 is a Phase 3 study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by vTv Therapeutics. The registered enrollment target is 150 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06334133, a Phase 3 study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by vTv Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cadisegliatin 800 mg QD
- DRUG Cadisegliatin 800 mg BID
Study Locations (20)
California
- Advanced Metabolic Care & Research Institute, Inc. (AMCR) - Escondido
- MD Studies, Inc - Fountain Valley
- AME Clinical Research - Huntington Beach
- 310 Clinical Research - Inglewood
- Scripps Whittier Diabetes Institute - La Jolla
- Paradigm Clinical Research - Modesto - Modesto
- Amicis Research Center - Northridge
- Velocity Clinical Research - San Bernardino
- Paradigm Clinical Research Centers LLC - San Diego
- Acclaim Clinical Research - San Diego
- Focus Clinical Research - West Hills
Florida
- BayCare Health Systems - Clearwater
- ALL Medical Research, LLC - Cooper City
- Excellence Medical and Research - Miami Gardens
- Metabolic Research Institute, Inc - West Palm Beach
Georgia
- Atlanta Diabetes Associates - Atlanta
- East Coast Institute for Research, LLC - Canton
Arizona
- Scottsdale Clinical Trials - Scottsdale
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Colorado
- Denver Endocrinology Diabetes and Thyroid Center - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06334133
The ClinicalTrials.gov registry entry for NCT06334133 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (88% lower). The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06334133 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06334133 about?
NCT06334133 is a clinical study titled "Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes". This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
What is the current status of trial NCT06334133?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-06-14. Estimated completion is 2026-10.
What conditions does trial NCT06334133 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT06334133?
The interventions under investigation include: Placebo (DRUG), Cadisegliatin 800 mg QD (DRUG), Cadisegliatin 800 mg BID (DRUG).
Who is sponsoring clinical trial NCT06334133?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06334133 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
RECRUITING · Phase 3
-
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
RECRUITING · Phase 3
-
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
RECRUITING · Phase 3
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.